BOSTON and LONDON, October 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company …
NOTICE & RESULTS OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON THURSDAY, NOVEMBER 7, 2024
RESULTS OF GENERAL MEETING OF SHAREHOLDERS - NOVEMBER 7, 2024 NOTICE OF GENERAL MEETING OF SHAREHOLDERS - NOVEMBER 7, 2024 GENERAL MEETING FORM OF PROXY …
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
BOSTON and LONDON, September 17, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced …
[Read more...] about Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Akari Therapeutics Reports Second Quarter – 2024 Financial Results and Recent Highlights
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s …
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic …
